Bridging the divide:
Engineering FLASH therapy for the clinic.
For decades, radiation therapy has faced a fundamental compromise: delivering enough radiation to destroy cancer cells without inflicting debilitating damage on surrounding healthy tissue. While the discovery of the FLASH effect promised to shatter this trade-off, moving ultra-high-dose-rate delivery from laboratory trials to actual patient treatment beds requires extraordinary engineering and rigorous validation. In Episode 3 of The FLASH Effect, TibaRay Co-Founder and Board Member Dr. Peter Maxim—Professor and Vice Chair of Medical Physics at UC Irvine—joins host Justin Starbird to unpack how TibaRay is rethinking linear accelerators, real-time dosimetry, and beam control to bring sub-second cancer treatment into routine clinical reality.
The full conversation
Dr. Peter Maxim in conversation with Justin Starbird
Take the conversation with you
Episode 3 on Spotify
Explore the transcript
Read the complete interview transcript at your own pace.
Read Full TranscriptComplete unedited transcript from the recorded interview.
The physics.
The engineering.
The clinical path.
- The role of medical physics in delivering submillimeter radiation accuracy safely to cancer patients
- The origin of TibaRay: translating SLAC accelerator physics and Stanford clinical insights into a scalable medical device
- Eliminating the organ motion barrier by delivering radiation faster than physiological motion—between two heartbeats
- The 2014 Curie Institute discovery and reproducible global preclinical validation of the normal-tissue-sparing FLASH effect
- Why conventional linear accelerators and daily clinical dose-measurement instrumentation cannot keep up with ultra-fast radiation
- TibaRay's engineered solutions: overcoming next-generation accelerator hardware, power, and beam control challenges
- What clinicians, institutions, and regulators need to see: independent beam verification and human clinical trials
- Bridging MedTech's "valley of death": how strategic and community investment via Wefunder fuels industrial-scale commercialization
The conversation explores technology under development and its potential. Clinical validation remains part of the road ahead.